| Cash Flow | 2025-06-30 |
|---|---|
| Share-based compensation expense | 1,990 |
| Net (loss)/profit | -77,924 |
| Other | 56 |
| Decrease in noncurrent assets | -562 |
| Increase in inventories | 4,041 |
| Decrease in deferred revenue | -5,812 |
| (decrease)/increase in payables and other current liabilities | -11,407 |
| Unrealized foreign exchange gains | 888 |
| Depreciation | 4,620 |
| Amortization | 355 |
| Increase in borrowings and other non-current liabilities | 784 |
| (increase)/decrease in receivables and other operating assets | 9,158 |
| Accretion of available-for-sale debt securities | 509 |
| Net cash (used in)/provided by operating activities | -101,372 |
| Other | 62 |
| Maturity, redemption or sale of marketable securities | 76,950 |
| Acquisition of property, plant and equipment | 1,278 |
| Investment in marketable securities | 16,090 |
| Net cash provided by/(used in) investing activities | 59,644 |
| Repayment of borrowings | 25,451 |
| Proceeds from exercise of stock options | 10 |
| Proceeds from issuance of common stock from offerings, net of commissions and issuance costs | 1,775 |
| Net cash (used in)/provided by financing activities | -23,666 |
| Effect of currency exchange rate changes on cash, cash equivalents and restricted cash | -34 |
| Net (decrease)/increase in cash, cash equivalents and restricted cash | -65,428 |
Adaptimmune Therapeutics PLC (ADAP)
Adaptimmune Therapeutics PLC (ADAP)